Genmab — Oktober 2017
-
based on cross-trial comparisons, it has demonstrated faster B-cell repletion. These factors could determine that ofatumumab is a more patient and physician-friendly treatment, argues Novartis; a view shared by KOLs recently interviewed by FirstWord for our forthcoming report. Phase III studies should complete in 2019.
-
God morgen:-)
-
6:43
-
@Sukkeralf: Hvor stort mon the potentielle marked er for Ofatumumab og hvornår begynder der mon at komme pæne betalinger til Genmab
-
-
Stock bull er spået til at blive multi BB - tror det var 3-4 millarder dollars i omsætning. Så lad os håbe at Novartis kan få et BB stof ud af ofatumumab, hvis data er gode. En godkendelse kan være i hus i 2020 og royalty for de autoimmune sygdomme ligger vist på 15% eller husker jeg forkert ?
-
On Teprotumumab I add the link to the genmab site
(i doubt many will know it has anything to do with Genmab...) http://www.genmab.com/product-pipeline/products-in-development/teprotumumab#tab1 -
@ JørgenVarnæs, du nævte tidligere noget omkring de to primære konkurrenters salgstal og at disse, ville være tilgængelige 26. Oktober. Har du adgang til disse? Kan du kommentere på deres salgstal og udvikling i markedsandele for de tre produkter, over de 3. første kvartaler?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind